neoadjuvant chemotherapy) was significantly higher in tumour 4cm (65% vs 20%) (p¼0.0001). Definitive chemoradiation was more indicated in larger tumours, without statistical significance (75% vs 46%)(p¼0.4). Therapeutic discordance between the planned and the administered treatment was significantly higher in larger tumours (68% vs 18%) (p¼0.0001). Progression free survival was longer in smaller tumours (18±9.3 vs 11±12.1 months) without being statistically significant. However, median overall survival was significantly correlated with tumour size (41.7± 5.1 in 4 cm, 32.8±4.6 months in > 4 cm) (p¼0.04). The pattern of recurrence was not correlated to tumour size; it was locoregional in 30%, distant in 20% and both locoregional/distant in 50% in4 cm group vs 42%, 24%, and 34% respectively in tumour size> 4 cm (p¼0.6). Conclusion:When taking 4 cm as a cut-off value, tumour size influenced clinical presentation and management modalities. It may be considered as a prognostic factor in stage III NSCLC.